Literature DB >> 19750867

Classic virilizing congenital adrenal hyperplasia presenting late: case series from Pakistan.

Aysha Habib Khan1, Muniba Aban, Jamal Raza, Abdul Jabbar, Tariq Moatter.   

Abstract

Deficiency of 21 hydroxylase enzyme deficiency (21OH) activity accounts for 90% cases of congenital adrenal hyperplasia (CAH). This results in deficient cortisol, increased ACTH, adrenal hyperplasia and increased adrenal androgen secretion. There is marked virilization in genetic females which is the hallmark of this disorder. Genetic heterogeneity in 21 OHD is well recognized, and both severe and mild forms occur. We present three cases of adult females with the disease from a larger study to establish genotype, phenotype correlation of Pakistani patients with congenital adrenal hyperplasia (CAH) and to highlight issues such as diagnostic delay, inappropriate gender assignment at birth, and high degree of consanguinity among parents, psychosexual outcome of 21 OHD females and the need to develop expertise for early case detection. The analysis was done using Amplification Refractory Mutation System (ARMS) PCR. These cases show that CAH frequently remains undiagnosed during the newborn period in our population due to lack of awareness in the society and lack of proper diagnosis by the primary physician. There is a need to develop expertise for early case detection.

Entities:  

Mesh:

Year:  2009        PMID: 19750867

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  2 in total

1.  Ethnic disparity in 21-hydroxylase gene mutations identified in Pakistani congenital adrenal hyperplasia patients.

Authors:  Aysha H Khan; Muniba Aban; Jamal Raza; Naeem Ul Haq; Abdul Jabbar; Tariq Moatter
Journal:  BMC Endocr Disord       Date:  2011-02-18       Impact factor: 2.763

Review 2.  Trends of congenital hypothyroidism and inborn errors of metabolism in Pakistan.

Authors:  Sumreena Mansoor
Journal:  Orphanet J Rare Dis       Date:  2020-11-14       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.